<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629393</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1101-MCD-202</org_study_id>
    <nct_id>NCT02629393</nct_id>
  </id_info>
  <brief_title>Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A</brief_title>
  <official_title>A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Origin Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Origin Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with
      MoCD Type A
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response, defined as patients alive and able to sit upright independently for at least 30 seconds</measure>
    <time_frame>At 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bayley Scales of Infant Development® - Third Edition (Bayley - III®)</measure>
    <time_frame>First 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Evaluation of Disability Inventory (PEDI)</measure>
    <time_frame>First 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Molybdenum Cofactor Deficiency, Type A</condition>
  <arm_group>
    <arm_group_label>ORGN001 (formerly ALXN1101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORGN001 (formerly ALXN1101)</intervention_name>
    <arm_group_label>ORGN001 (formerly ALXN1101)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the following inclusion criteria to be considered for enrollment
        in this study:

          1. Male or female neonatal patient (1 to 28 days of age [inclusive] at the time of
             ORGN001 administration, with day 1 of age corresponding to the day of birth) or infant
             (29 days to &lt;2 years of age) or child (2 to 5 years of age [inclusive]) with MoCD Type
             A, previously untreated with ORGN001 or treated with ORGN001 through the EAP

          2. In neonates, diagnosis of MoCD Type A, based on:

             Prenatal genetic diagnosis, or Onset of clinical and/or laboratory signs and symptoms
             consistent with MoCD Type A (eg, seizures, exaggerated startle response, high-pitched
             cry, axial hypotonia, limb hypertonia, feeding difficulties, elevated urinary sulfite
             and/or SSC, elevated xanthine in urine or blood, or low or absent uric acid in the
             urine or blood) within the first 28 days after birth

          3. In infants or children, diagnosis of MoCD Type A, based on:

             Confirmed genetic diagnosis (genetic confirmation of the diagnosis of MoCD Type A may
             be obtained after initiation of ORGN001 therapy in certain cases), biochemical
             profile, and clinical presentation consistent with MoCD Type A

          4. Parent or legal guardian must have signed the informed consent form (ICF) prior to any
             study procedures being performed

        Patients will be excluded from participating in the study if they meet any of the following
        criteria:

          1. Diagnosis other than MoCD Type A (may be determined after the initiation of study
             drug)

          2. Condition that is considered by the treating physician to be a contraindication to
             therapy, including evidence of abnormalities on brain imaging not attributable to MoCD
             Type A, or that might otherwise interfere with the patient's participation in the
             study, pose any additional risk for the patient, or confound patient assessments

          3. Antenatal and/or postnatal brain imaging prior to initiation of treatment with ORGN001
             that indicates cortical or subcortical cystic encephalomalacia, clinically significant
             intracranial hemorrhage, or other abnormalities on brain imaging determined by the
             treating physician to be clinically significant

          4. Modified Glasgow Coma Scale (mGCS) for Infants and Children score of less than 7 for
             more than 24 hours (does not apply to children less than 1 day in age).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liza Squires, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Origin Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Origin Biosciences (Sponsor)</last_name>
    <phone>1-617-322-5165</phone>
    <email>clinicaltrials@origintx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hosptial of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Origin Biosciences</last_name>
    </contact>
    <investigator>
      <last_name>Kara Pappas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lyon - Hôpital Femme Mère- Enfant</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18341</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Willink Biochemical Genetics Unit</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Molybdenum Cofactor Deficiency (MoCD)</keyword>
  <keyword>Molybdenum Cofactor (MoCo) biosynthesis</keyword>
  <keyword>sulfite oxidase (SO)</keyword>
  <keyword>S sulfocysteine (SSC)</keyword>
  <keyword>xanthine oxidoreductase</keyword>
  <keyword>aldehyde oxidase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

